Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Micawber who wrote (309)	12/15/1999 9:52:00 AM
From: scaram(o)uche	Read Replies (3) \| Respond to of 673

Brian: I want Ligand to succeed. They have chosen a strange route to success, addressing small markets and actually pursuing them after the strategy had already induced bleeding. I know that the cry is "off label". They need to get a label first. Then they need to find an indication where the off-label use makes sense in light of side effects. If anyone wants to pursue the earliest "red flag" posts, access (don't know that one can actually do such) the misc.invest.stocks archives and look for a Ligand post on or around 5/8/95. I attended a seminar that day by Heyman and Gill at the San Diego VA. Good science, great concepts, a CEO that has abused his shareholders. I've been correct about the "dilution" issue for some time, and I see no reason that it will end now. Hope it will, and that the company can catch up with its policy of deficit spending. Definitely not among biotech's best bargains, but I'm not going to predict a direction near-term. The simple question is, and this has been OBVIOUS for some time..... are the individuals that are looking to off label use justified given the side effects? I won't presume to know the answer, but I will say that the LGND gurus (Murphy, etc.) have obviously been among biotech's worst investors over a prolonged period. They tend to pick companies that lack leverage. I hope that LGND turns here and begins a steady ascent. Rick

To: Micawber who wrote (309)	12/15/1999 7:22:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 673

Today's PR.... really looks tacky to those who follow this stuff. There was nothing new, that I could see...... and I think this is the fourth mouse/rat "variation on theme" release over a couple of years, at least. Get some new material, David! It's sort of like..... "sorry, folks, but, after all this time and all those millions of dollars, we only have this old stuff to stem the bleeding". Every other company that I know of sort of let's the publication silently appear if a previous presentation has already been hyped. The company is very much alive and kicking, but..... it could have been so much more. This has been a unique situation, well worth the study. Imagine the course of LGND history if Levin had been CEO.